Tenofovir alafenamide (TAF) is a novel nucleotide reverse transcriptase inhibitor (NtRTI) developed by Gilead Sciences. As an advanced prodrug of tenofovir disoproxil fumarate (TDF), it is indicated for the treatment of hepatitis B virus (HBV) infection, human immunodeficiency virus (HIV) infection, and compensated liver disease.
GMP、DMF
